

RISK TO LAB STAFF FROM COVID-19

Faridabad: Covid-19 testing facility to build new team after 'around 60% staff' contract virus,

Ref: INDIAN EXPRESS, June 15, 2020, indianexpress.com/article/cities/delhi/faridabad-news-updates-staff-covid-19-testing-facility-contract-virus-6458956/

UP: COVID-19 test stopped at BHU lab as scientist becomes infected.

Ref: THE TIMES OF INDIA, May 1, 2020, http://timesofindia.indiatimes.com/articleshow/75489825.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

Indore: COVID-19 lab doctor tests positive for coronavirus

Ref: FINANCIAL EXPRESS, April 19, 2020, <https://www.financialexpress.com/lifestyle/health/indore-covid-19-lab-doctor-tests-positive-for-coronavirus/1933533/>

"The potential for a laboratory-acquired SARS-CoV-2 infection, causing COVID-19 disease, from accidental exposure grows as the pandemic progresses making the biosafety of samples during transportation and laboratory diagnosis is vital. CDC recommends VTM that preserve viability & infectivity of SARS-CoV-2 virus. Some healthcare professionals and transport personnel may not be aware that they are handling live viruses collected in this media.

Modern molecular nucleic acid (NA) tests, unlike traditional virology tests, do not require viable virus, but rather only intact NA particles of the viral genome.

A variety of transport media have previously shown to effectively inactivate/ kill viral, bacterial and fungal pathogens. These media include ones with a surfactant (e.g. Guanidine thiocyanate) ...

Moving to virus-inactivating VTM at collection allows risk mitigation from transportation and handling of bio-specimens for diagnosis and can potentially reduce the need for special packaging and transportation measures for SARS-CoV-2/COVID-19 test samples."(3)

SafeShield™ -VLTM

Viral Lysis Transport Medium*

For Molecular testing of RNA and DNA employing amplification tests

- Inactivates Microbes
- Solubilises Proteins
- Protects Nucleic Acids For Detection
- Protects Laboratorians From Infections



REF	203220250050
Σ	50 Tests

* Patent pending

REFERENCES

1. Kathy Luinstra, Astrid Petrich, Santina Castriciano, Mona Ackerman, Sylvia Chong, Susan Carruthers, Brenna Ammons, James B Mahony, Marek Smieja, Evaluation and Clinical Validation of an Alcohol-Based Transport Medium for Preservation and Inactivation of Respiratory Viruses, J Clin Microbiol. 2011 Jun; 49 (6):2138-42. doi: 10.1128/JCM.00327-11. Epub 2011 Apr 20.
2. Jamie A Blow, David J Dohm, Diane L Negley, Christopher N Mores, Virus Inactivation by Nucleic Acid Extraction Reagents, J Virol Methods. 2004 Aug;119 (2):195-8. doi: 10.1016/j.jviromet.2004.03.015
3. Rajan Dewar, David Baunoch, Kirk Wojno, Vinita Parkash, Roya Khosravi-Far, Viral transportation in COVID-19 pandemic: inactivated virus transportation should be implemented for safe transportation and handling at diagnostics laboratories, College of American Pathologists, Archives of Pathology and Laboratory Medicine, 2020, doi: 10.5858/arpa.2020-0175-LE.

Protect Our Warriors with

SafeShield™ -VLTM

For further information contact

Microexpress

A Division of Tulip Diagnostics (P) Ltd.

Plot No. S-124, S-125, S-126, Utility Plot No. VIII, Phase III-B, Verna Industrial Estate, Verna, Goa - 403 722, INDIA.

Regd. Office: Gitanjali, Tulip Block, Dr. Antonio Do Rego Bagh, Alto Santacruz, Bambolim Complex P.O., Goa - 403 202, INDIA.

Email: mex.queries@tulipgroup.com



ISO 13485
Certified Company